XELIRI compared with FOLFIRI as a second-line treatment in patients with metastatic colorectal cancer

Lignende værker

• UGT1A1*6, UGT1A7*3 and UGT1A9*1b polymorphisms are predictive markers for severe toxicity in patients with metastatic gastrointestinal cancer treated with irinotecan-based regimens
  af: Cui, Chengxu, et al.
  Udgivet: (2016)
• Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
  af: Ottaiano, Alessandro, et al.
  Udgivet: (2019)
• Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab
  af: Kotaka, Masahito, et al.
  Udgivet: (2016)
• Randomized Phase 3 Study of Panitumumab With FOLFIRI vs. FOLFIRI Alone as Second-Line Treatment in Patients With Metastatic Colorectal Cancer
  af: Ducreux, M., et al.
  Udgivet: (2010)
• FOLFIRI as second-line treatment of metastatic biliary tract cancer patients
  af: Rafael Caparica, et al.
  Udgivet: (2019)